In a recent letter (read below) from Pfizer, it was revealed that a young boy participating in their gene therapy trial for Duchenne muscular dystrophy (DMD) has passed away. The trial, known as Daylight, aimed to study the effects of Pfizer's experimental gene therapy, called fordadistrogene movaparvovec, on boys aged 2 to 3 years old.

The boy had received the gene therapy in early 2023, but the details surrounding his death are still unclear. Pfizer is actively working with investigato...